CSIMarket
 


Intellia Therapeutics Inc   (NTLA)
Other Ticker:  
 

Intellia Therapeutics Inc 's Tangible Leverage Ratio

NTLA's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 106.24%, Tangible Leverage Ratio fell to 0.2, below the Intellia Therapeutics Inc 's average Tangible Leverage Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry in the third quarter 2023, 2 other companies have achieved lower Tangible Leverage Ratio than Intellia Therapeutics Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 196 to 412 .

Explain Tangible Leverage Ratio?
What is NTLA Market Share?
What are NTLA´s Total Liabilities?


NTLA Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change 25.75 % 25.48 % 24.86 % 18.78 % -25.49 %
Y / Y Total Liabilities Change 57.04 % -56.56 % -58.49 % -50.22 % -42.45 %
Tangible Leverage Ratio MRQ 0.2 0.09 0.09 0.1 0.16
NTLA's Total Ranking # 412 # 196 # 100 # 213 # 338
Seq. Tangible Equity Change -6.11 % -7.22 % -3.62 % 49.78 % -6.31 %
Seq. Total Liabilities Change 106.24 % -3.42 % -18.31 % -3.49 % -42.96 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 219
Overall Market # 412


Tangible Leverage Ratio Statistics
High Average Low
0.42 0.28 0.09
(Dec 31 2016)   (Mar 31 2023)




Financial Statements
Intellia Therapeutics Inc 's Tangible Equity $ 1,037 Millions Visit NTLA's Balance sheet
Intellia Therapeutics Inc 's Total Liabilities $ 206 Millions Visit NTLA's Balance sheet
Source of NTLA's Sales Visit NTLA's Sales by Geography


Cumulative Intellia Therapeutics Inc 's Tangible Leverage Ratio

NTLA's Tangible Leverage Ratio for the trailling 12 Months

NTLA Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth 25.75 % 25.48 % 24.86 % 18.78 % -25.49 %
Y / Y Total Liabilities TTM Growth 57.04 % -56.56 % -58.49 % -50.22 % -42.45 %
Tangible Leverage Ratio TTM 0.12 0.11 0.14 0.19 0.23
Total Ranking TTM # 2 # 2 # 2 # 1 # 122
Seq. Tangible Equity TTM Growth -6.11 % -7.22 % -3.62 % 49.78 % -6.31 %
Seq. Total Liabilities TTM Growth 106.24 % -3.42 % -18.31 % -3.49 % -42.96 %


On the trailing twelve months basis Due to the net new borrowings of 106.24% during the trailing twelve months finishing in the III Quarter 2023, cumulativeTangible Leverage Ratio improved to 0.12, below the Intellia Therapeutics Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the In Vitro & In Vivo Diagnostic Substances industry 2, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Intellia Therapeutics Inc . While total ranking remained unchanged compared to previous 12 month period at no. 2.

Explain Tangible Leverage Ratio?
What is NTLA Market Share?
What are NTLA´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 219
Within the Market # 2


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.42 0.28 0.09
(Dec 31 2016)   (Mar 31 2023)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Alpha Teknova Inc   0.47 $ 38.733  Millions$ 82.956  Millions
Biomerica Inc   0.23 $ 2.451  Millions$ 10.566  Millions
Intellia Therapeutics Inc   0.20 $ 205.935  Millions$ 1,037.414  Millions
Celldex Therapeutics inc   0.15 $ 33.538  Millions$ 219.528  Millions

Date modified: 2023-11-12T12:09:22+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com